Analysts Viewpoint Understanding the Risks of Investing in KalVista Pharmaceuticals Inc (KALV) KalVista Pharmaceuticals Inc’s recent filing unveils that its 10% Owner Venrock Healthcare Capital Par acquired Company’s shares for reported $0.24